Ingvarsson Sigurdur
Institute for Experimental Pathology, University of Iceland at Keldur, v/Vesturlandsveg, IS-112 Reykjavik, Iceland.
Drugs Today (Barc). 2004 Dec;40(12):991-1002. doi: 10.1358/dot.2004.40.12.872574.
Breast cancer has all the hallmarks of a multistep genetic disease. Somatic and germ-line mutations have been described in several tumor suppressor genes, and oncogenes are found to be amplified. Genes in the ATM-CHK2-TP53 cell-cycle checkpoint pathway are mutated in relation to breast cancer, particularly TP53 at the somatic level. Germ-line mutations in BRCA1 and BRCA2, in which DNA repair function is interrupted, account for the majority of familial breast cancers. The mechanism behind the frequent instability of the genomes of breast cancer cells has been poorly understood, but recent functional findings on oncogenes and tumor suppressor genes have provided substantial information on the matter. Some recent developments in drug therapy are based on molecular and genomic findings about breast cancer pathogenesis.
乳腺癌具有多步骤遗传疾病的所有特征。已在多个肿瘤抑制基因中描述了体细胞和种系突变,并且发现癌基因会扩增。ATM-CHK2-TP53细胞周期检查点途径中的基因与乳腺癌相关发生突变,尤其是在体细胞水平上的TP53。BRCA1和BRCA2中的种系突变会中断DNA修复功能,是大多数家族性乳腺癌的病因。乳腺癌细胞基因组频繁不稳定背后的机制一直未得到充分理解,但最近关于癌基因和肿瘤抑制基因的功能研究结果为此提供了大量信息。药物治疗方面的一些最新进展是基于有关乳腺癌发病机制的分子和基因组研究结果。